Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)

Study Overview

Primary Objectives:

Dose Escalation: Part A (SAR439859 monotherapy); Part C (combination of SAR439859 with palbociclib); Part F (combination of SAR439859 with alpelisib)

  • To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR439859 based on the dose-limiting toxicity observance in monotherapy (Part A), in combination with palbociclib (Part C) and in combination with alpelisib (Part F)

Dose Expansion: Part B (SAR439859 monotherapy):

  • To assess antitumor activity by Objective Response Rate (ORR) at the SAR439859 recommended dose in monotherapy

Dose Expansion: Part D (combination of SAR439859 with palbociclib) and Part G (combination of SAR439859 with alpelisib):

  • Overall safety profile of SAR439859 in combination with palbociclib and alpelisib

Midazolam Drug-Drug Interaction Sub-Study: Part E

  • To assess the effect of SAR439859 on CYP3A enzyme activity using midazolam as a probe

Secondary Objectives:

  • Overall safety profile of SAR439859 as monotherapy (Parts A, B, E), in combination with palbociclib (Part C) or in combination with alpelisib (Part F)
  • Pharmacokinetic (PK) profile of SAR439859 as monotherapy (Parts A, B, E), in combination with palbociclib (Parts C, D, E), in combination with alpelisib (Parts F, G, E), and PK of palbociclib (Parts C, D) and alpelisib (Parts F, G) alone and/or with SAR439859
  • Antitumor activity of SAR439859 as monotherapy (Part A, E), in combinations with palbociclib (Part C, D, E) or alpelisib (F, G, E), and Clinical Benefit Rate (CBR: Complete Response [CR], Partial Response [PR] and Stable Disease [SD] =24 weeks) in Parts A, B, C, D, E, F, G
  • ORR and CBR in Parts B, D, E and G according to the estrogen receptor 1 (ESR1) gene mutational status (mutant and wild type) at baseline and in treatment
  • Time to first tumor response (CR,PR) (Part B, D, G)
  • Residual estrogen receptor (ER) availability with [(18)F] Fluoroestradiol Positron Emission Tomography (FES PET) scan (Part A)
  • To assess potential induction/inhibition effect of SAR439859 on CYP3A (Part A, B, E)

Study Description

A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer

  • Identifier: NCT03284957
  • Protocol Number: 17-371
  • Principal Investigator: Jaymin Patel

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000